Valuation Highnoon Laboratories Limited

Stocks

End-of-day quote Pakistan S.E. 2026-09-04			5-day change	1st Jan Change
930.78 ^PKR	-0.68%		-2.07%	-8.97%

08-27	Highnoon Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
05-18	Highnoon Laboratories Appoints Dr. Shahzad Khan as Managing Director of Highnoon Life Sciences	CI

Data adjusted to current consolidation scope

Fiscal Period: December	2024	2025	2026	2027	2028
Market Cap ¹	48,650	54,175	49,316	-	-
Change	-	11.36%	-8.97%	-	-
Enterprise Value (EV)	48,650	54,175	49,316	49,316	49,316
Change	-	11.36%	-8.97%	0%	0%
P/E	14.4x	-	-	-	-
PBR	-	-	-	-	-
PEG	-	-	-	-	-
Capitalization / Revenue	-	1.96x	1.62x	1.44x	1.28x
EV / Revenue	-	0x	1.62x	1.44x	1.28x
EV / EBITDA	-	-	-	-	-
EV / EBIT	-	-	-	-	-
EV / FCF	-	-	-	-	-
FCF Yield	-	-	-	-	-
Dividend per Share ²	-	50	45	52	60
Rate of return	-	4.89%	4.83%	5.59%	6.45%
EPS ²	63.95	-	-	-	-
Distribution rate	-	-	-	-	-
Net sales ¹	-	27,706	30,398	34,163	38,399
EBITDA	-	-	-	-	-
EBIT	-	-	-	-	-
Net income	3,389	-	-	-	-
Net Debt	-	-	-	-	-
Reference price ²	918.22	1,022.49	930.78	930.78	930.78
Nbr of stocks (in thousands)	52,983	52,983	52,983	-	-
Announcement Date	3/26/25	4/7/26	-	-	-

¹PKR in Million²PKR

Estimates

Add to a list 0 selected To use this feature you must be a member Log in Sign up	P/E (Y)	EV / Sales (Y)	EV / EBITDA (Y)	Dividend Yield (Y)	Capi.($)
HIGHNOON LABORATORIES LIMITED	-	-	-	4.83%	178M
ELI LILLY AND COMPANY	32.72x	11.9x	24.26x	0.6%	1,024B
JOHNSON & JOHNSON	30.62x	-	-	1.95%	663B
ABBVIE INC.	32.73x	7.6x	15.8x	2.67%	453B
ROCHE HOLDING AG	19.89x	4.73x	11.71x	2.8%	352B
NOVARTIS AG	22.72x	5.84x	14.51x	2.7%	304B
ASTRAZENECA PLC	20.87x	4.29x	12.24x	2.06%	252B
AMGEN INC.	27.66x	7.14x	13.15x	2.31%	236B
NOVO NORDISK A/S	13.33x	4.82x	10.06x	3.78%	206B
GILEAD SCIENCES, INC.	-46.14x	6.65x	25.95x	2.18%	187B
Average	17.16x	6.62x	15.96x	2.59%	367.85B
Weighted average by Cap.	24.05x	7.99x	17.80x	1.95%